ブロモクリプチンメシル酸塩

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H410：長期的影響により水生生物に非常に強い毒性

• 注意書き

  P273：環境への放出を避けること。

ブロモクリプチンメシル酸塩 価格

ブロモクリプチンメシル酸塩 化学特性,用途語,生産方法

• 外観

  白色～わずかにうすい褐色, 結晶性粉末～粉末

• 溶解性

  エタノール(95)にやや溶けにくく、水にほとんど溶けない。

• 用途

  ドーパミンD2 レセプターの アゴニストです。

• 効能

  パーキンソン病治療薬, ドパミンD2受容体作動薬, プロラクチン阻害薬

• 商品名

  パーロデル (サンファーマ)

• 説明

  Bromocriptine is a dopamine receptor agonist (K_is = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D₁, D₂, D₃, D₄, and D₅ receptors, respectively). It also binds to the serotonin (5-HT) receptor subtypes 5-HT_1A and 5-HT_1D (K_is = 12.9 and 10.7 nM, respectively), as well as α₁-adrenergic receptors (K_is = 1.12-4.17 nM). Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP. Formulations containing bromocriptine have been used in the treatment of Parkinson''s disease, hyperprolactinemia-associated dysfunctions, and acromegaly.

• 化学的特性

  Solid

• 使用

  Dopamine receptor agonist; derivative of the ergotoxin group of ergot alkaloids. Prolactin inhibitor; antiparkinsonian.

• 一般的な説明

  Bromocriptine mesylate,(6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate(Parlodel), is a white solid soluble in ethanol and slightly solublein water (pK_a’s＝6.6 and 15). Bromocriptine is rapidlyabsorbed after oral administration and it has low systemicbioavailability because of its extensive first-pass metabolism.Bromocriptine enters the brain quickly with a half-lifefor uptake into the brain of approximately 0.3 hours; 8% ofthe drug crosses the BBB.The metabolites are excreted primarilyin the bile and feces. The high first-pass hepatic metabolismimplies an increased risk of drug interactions.Concomitant administration with the DA antagonists, metoclopramide,or domperidone may aggravate parkinsoniansymptoms and induce extrapyramidal side effects (EPS).Other drugs that may interact with bromocriptine are highlyplasma protein–bound drugs (e.g., warfarin, increased dyskinesiacaused by bromocriptine); macrolides antibacterials(enhanced dopaminergic effects); and caffeine (elevation inplasma bromocriptine concentrations). The combination oflevodopa/AADC inhibitors with bromocriptine permits a reductionof the dose of levodopa. Thus, the side effects oflevodopa are decreased, resulting in a more continuous stimulationof DA receptors.

• 生物活性

  Selective D 2 -like dopamine receptor agonist (K i values are ~ 8, ~ 5, ~ 290, ~ 440 and ~ 450 nM for D 2 , D 3 , D 4 , D 1 and D 5 receptors respectively).

ブロモクリプチンメシル酸塩 上流と下流の製品情報

ブロモクリプチンメシル酸塩 生産企業

Global(296)Suppliers

ブロモクリプチンメシル酸塩 スペクトルデータ(¹HNMR)

22260-51-1, ブロモクリプチンメシル酸塩 キーワード